Your search history is turned on.
Date: March 26, 2024 Jurisdictions: Alberta, British Columbia, Ontario
1 MARVEL BIOSCIENCES CORP. MANAGEMENTS DISCUSSION AND ANALYSIS The following Managements Discussion and Analysis (MD&A) is dated March 26, 2024 and should be read in conjunction with the unaudited condensed interim consolidated financial statements for the six months ended January 31, 2024 and 2023, along with the audited consolidated financial sta...
MARVEL BIOSCIENCES CORP. Condensed Interim Consolidated Financial Statements For the Three and Six Months Ended January 31, 2024 and 2023 (Unaudited - expressed in Canadian Dollars) NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL ...
_ 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Harry Nijjar, Chief Financial Officer of Marvel Biosciences Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Marvel Biosciences Corp. (the issuer) for...
_ 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, J. Roderick Matheson, Chief Executive Officer of Marvel Biosciences Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Marvel Biosciences Corp. (the issu...
Date: March 25, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204 Calgary, Alberta March 25, 2024 Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel), today reported promising interim results from its acute stud...
Date: March 12, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - MarvelNewsMarch122024 MarvelBiosciencesAnnouncesPositiveInterim ResultsforAutismTreatmentwithMB204 Calgary,AlbertaMarch12,2024MarvelBiosciencesCorp.(TSXV:MRVLOTC:MBCOF),and itswhollyownedsubsidiary,MarvelBiotechnologyInc.(collecvelytheCompanyorMarvel),today reportedpromisinginterimresultsfromitsstudy...
Date: February 20, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Marve l Biosciences Announces Testing MB- 204 on Autism by French Unive rsity Feb 20, 2024| News Ca lga ry, Alb e r t a , Fe b ru a ry 20, 2024 - Ma rve l Bio scie n ce s Co rp . (TSXV: MRVL OTC: MBCOF) and its wholly owned subsid iary, Marve l Biotechnology Inc. (collective ly the Com p a n y or Ma rve l), is p leased to a...
Date: January 29, 2024 Jurisdictions: Alberta
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: January 23, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - 2024 01 23 Material Change Report FORM51102F3MATERIALCHANGEREPORT 1. NAMEANDADDRESSOFCOMPANY MarvelBiosciencesCorp. Suite420,5058thAvenueSW Calgary,Alberta T2P1G2 2. DATEOFMATERIALCHANGE January19,2024 3. NEWSRELEASE NewsreleasedatedJanuary19,2024wasdisseminatedthroughthefacilities...
Date: January 19, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NEWS RELEASE MARVEL BIOSCIENCES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT Calgary, Alberta, Canada, January 19, 2024 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the Company or Marvel), is pleased to announce the Company has closed a non-broker...